Reaching international GMP standards for vaccine production: challenges for developing countries.

Area of Science:

• Pharmaceutical manufacturing
• Vaccinology
• Regulatory science

Background:

• Good Manufacturing Practice (GMP) standards for vaccine production have historically been challenging for developing countries.
• Many public sector vaccine producers in developing nations operate under unvalidated national regulatory authorities (NRAs).
• Even manufacturers in industrialized nations faced difficulties adhering to GMP regulations upon their introduction.

Purpose of the Study:

• To assess the capacity of manufacturers in developing countries to meet Good Manufacturing Practice (GMP) standards.
• To evaluate the progress in GMP compliance using World Health Organization (WHO) prequalification as a global indicator.
• To examine the implications of these advancements for the global vaccine market.

Main Methods:

• The study utilizes World Health Organization (WHO) prequalification data as the primary metric for assessing GMP compliance.
• Analysis of trends in the number of national regulatory authorities (NRAs) capable of enforcing GMP standards in developing countries over time.
• Qualitative review of reported difficulties faced by manufacturers in achieving GMP standards.

Main Results:

• The number of developing country NRAs considered capable of enforcing GMP compliance has increased significantly since 1996.
• This rise in regulatory capacity correlates with an increase in the number of manufacturers meeting GMP standards.
• Specific challenges encountered by manufacturers in meeting GMP are detailed.

Conclusions:

• Developing country vaccine manufacturers are demonstrating increasing ability to meet global Good Manufacturing Practice (GMP) standards.
• The World Health Organization (WHO) prequalification process serves as a vital indicator of this improving capability.
• These advancements have positive implications for the future vaccine supply chain and market accessibility.